Researchers demonstrated that CD20 controlled the nanoscale organization of receptors on the surface of resting B lymphocytes.
[Proceedings of the National Academy of Sciences of the United States of America]
6445218 TFVZE7ET items 1 apa default asc 1
Kläsener, K., Jellusova, J., Andrieux, G., Salzer, U., Böhler, C., Steiner, S. N., Albinus, J. B., Cavallari, M., Süß, B., Voll, R. E., Boerries, M., Wollscheid, B., & Reth, M. (2021). CD20 as a gatekeeper of the resting state of human B cells. Proceedings of the National Academy of Sciences, 118(7). https://doi.org/10.1073/pnas.2021342118 Cite
The authors discuss their approach to relapsed or refractory diffuse large B cell lymphoma patients and the open question of optimal sequencing of autologous transplant , CAR-T therapy, and bispecific antibodies.
[Current Hematologic Malignancy Reports]
6445212 EIVLPBBS items 1 apa default asc 1
Doraiswamy, A., Shah, M. R., & Bannerji, R. (2021). Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports. https://doi.org/10.1007/s11899-021-00610-y Cite
Researchers assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed and relapsed/refractory B-cell non-Hodgkin lymphoma patients.
[Blood Cancer Journal]
6445218 RALZVNEA items 1 apa default asc 1
van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D. R. A. I., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M. E. D., Zweegman, S., Breij, E. C. W., Roemer, M. G. M., & Mutis, T. (2021). Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal, 11(2), 1–8. https://doi.org/10.1038/s41408-021-00430-6 Cite
The authors update our understanding of B cell biology, review the results of clinical trials using B cell depletion therapies (BCDT) in autoimmune indications, discuss hypotheses for the mechanism of action of BCDT and speculate on evolving strategies for targeting B cells beyond depletion.
[Nature Reviews Drug Discovery]
6445218 XVNGRP39 items 1 apa default asc 1
Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues | Scientific Reports. (n.d.). Retrieved October 27, 2020, from https://www.nature.com/articles/s41598-020-74996-9 Cite
Scientists employed laser microdissection and whole-transcriptome profiling of the breast epithelium prior to and post tumor diagnosis to identify the earliest alterations in breast carcinogenesis.
[npj Breast Cancer]
6807162 DH79SHP7 items 1 apa default asc 1
Researchers conduct a first-in-human trial of bispecific anti-CD20, anti-CD19 CAR T cells for relapsed, refractory B cell malignancies.
6445218 LP3EH4P8 items 1 apa default asc 1
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., Cunningham, A., Hamadani, M., Fenske, T. S., Dropulić, B., Orentas, R., & Hari, P. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine, 1–7. https://doi.org/10.1038/s41591-020-1081-3 Cite
Scientists report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms, negative IgG-IgM SARS-CoV-2 serology and a positive RNAemia measured by digital PCR who were treated with four units of COVID-19 convalescent plasma.
6445218 CWDLXPFJ items 1 apa default asc 1
Hueso, T., Pouderoux, C., Péré, H., Beaumont, A.-L., Raillon, L.-A., Ader, F., Chatenoud, L., Eshagh, D., Szwebel, T.-A., Martinot, M., Camou, F., Crickx, E., Michel, M., Mahevas, M., Boutboul, D., Azoulay, E., Joseph, A., Hermine, O., Rouzaud, C., … Lacombe, K. (n.d.). Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease. Blood. https://doi.org/10.1182/blood.2020008423 Cite
Associated markers of tertiary lymphoid structures (TLS), including peripheral node address in high endothelial venules, CD20 in B cells and CD3 in T cells, were examined in 168 oral squamous cell carcinoma patients, and survival analysis was performed between TLS-positive and TLS-negative cohorts.
[International Journal of Oral Science]
1254621 NHLFHMGS items 1 apa default asc 1
The authors developed a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics, including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor.
[npj Systems Biology and Applications]
6445212 7Q3VUWIV items 1 apa default asc 1
Hosseini, I., Gadkar, K., Stefanich, E., Li, C.-C., Sun, L. L., Chu, Y.-W., & Ramanujan, S. (2020). Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. Npj Systems Biology and Applications, 6(1), 1–11. https://doi.org/10.1038/s41540-020-00145-7 Cite
Analysis of splenic artery aneurysms revealed the presence of atherosclerotic lesions, calcifications, and intraluminal thrombus. Splenic artery aneurysms were characterized by a profound vascular remodeling with a dramatic loss of vascular smooth muscle cells, elastin degradation, adventitial fibrosis associated with enhanced apoptosis, and increased matrix metalloproteinase 9 expression.
6445218 MEDQIMTN items 1 apa default asc 1
Clément, M., Lareyre, F., Loste, A., Sannier, A., Burel-Vandenbos, F., Massiot, N., Carboni, J., Jean-Baptiste, E., Caligiuri, G., Nicoletti, A., & Raffort, J. (2020). Vascular Remodeling and Immune Cell Infiltration in Splenic Artery Aneurysms: Angiology. https://doi.org/10.1177/0003319720952290 Cite